-
1
-
-
3242775982
-
Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock
-
Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-73.
-
(2004)
Crit Care Med
, vol.32
, pp. 858-873
-
-
Dellinger, R.P.1
Carlet, J.M.2
Masur, H.3
-
2
-
-
0037090339
-
Clinical trials of immunomodulatory therapies in severe sepsis and septic shock
-
Vincent J-L, Sun Q, Dubois M-J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34:1084-93.
-
(2002)
Clin Infect Dis
, vol.34
, pp. 1084-1093
-
-
Vincent, J.-L.1
Sun, Q.2
Dubois, M.-J.3
-
3
-
-
3543117815
-
Macrolide activities beyond their antimicrobial effects: Macrolides in diffuse panbronchiolitis and cystic fibrosis
-
Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54:21-8.
-
(2004)
J Antimicrob Chemother
, vol.54
, pp. 21-28
-
-
Schultz, M.J.1
-
4
-
-
0036001168
-
Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors
-
Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 2002; 49:745-55.
-
(2002)
J Antimicrob Chemother
, vol.49
, pp. 745-755
-
-
Kikuchi, T.1
Hagiwara, K.2
Honda, Y.3
-
5
-
-
0347361713
-
Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa
-
Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48:93-9.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 93-99
-
-
Giamarellos-Bourboulis, E.J.1
Adamis, T.2
Laoutaris, G.3
-
6
-
-
12344261855
-
Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli
-
Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, et al. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli. Int J Antimicrob Agents 2005; 25:168-72.
-
(2005)
Int J Antimicrob Agents
, vol.25
, pp. 168-172
-
-
Giamarellos-Bourboulis, E.J.1
Baziaka, F.2
Antonopoulou, A.3
-
7
-
-
13644266012
-
Clarithromycin: Immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli
-
Giamarellos-Bourboulis EJ, Adamis T, Sabracos L, et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 2005; 37:48-54.
-
(2005)
Scand J Infect Dis
, vol.37
, pp. 48-54
-
-
Giamarellos-Bourboulis, E.J.1
Adamis, T.2
Sabracos, L.3
-
8
-
-
33644929201
-
Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistantPseudomonas aeruginosa
-
Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistantPseudomonas aeruginosa. BMC Infect Dis 2006; 6:31.
-
(2006)
BMC Infect Dis
, vol.6
, pp. 31
-
-
Giamarellos-Bourboulis, E.J.1
Antonopoulou, A.2
Raftogiannis, M.3
-
9
-
-
33645804394
-
Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae
-
Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, et al. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2006; 57:937-44.
-
(2006)
J Antimicrob Chemother
, vol.57
, pp. 937-944
-
-
Giamarellos-Bourboulis, E.J.1
Tziortzioti, V.2
Koutoukas, P.3
-
10
-
-
0034949783
-
Ventilator-associated pneumonia in a surgical intensive care unit: Epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling
-
Woske HJ, Röding T, Schulz I, Lode H. Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. Crit Care 2001; 5:167-73.
-
(2001)
Crit Care
, vol.5
, pp. 167-173
-
-
Woske, H.J.1
Röding, T.2
Schulz, I.3
Lode, H.4
-
11
-
-
13644257785
-
Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: A role for routine endotracheal aspirate cultures
-
Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 2005; 127:589-97.
-
(2005)
Chest
, vol.127
, pp. 589-597
-
-
Michel, F.1
Franceschini, B.2
Berger, P.3
-
13
-
-
17944370018
-
-
Rello J, Paiva JA, Baraibar J, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001; 120:955-70.
-
Rello J, Paiva JA, Baraibar J, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001; 120:955-70.
-
-
-
-
14
-
-
0141785587
-
Diagnosis of ventilator-associated pneumonia
-
Baughman RP. Diagnosis of ventilator-associated pneumonia. Curr Opin Crit Care 2003; 9:397-402.
-
(2003)
Curr Opin Crit Care
, vol.9
, pp. 397-402
-
-
Baughman, R.P.1
-
15
-
-
3543151410
-
Ventilator-associated pneumonia
-
Vincent JL. Ventilator-associated pneumonia. J Hosp Infect 2004; 57:272-80.
-
(2004)
J Hosp Infect
, vol.57
, pp. 272-280
-
-
Vincent, J.L.1
-
16
-
-
0025809112
-
Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid
-
Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121-9.
-
(1991)
Am Rev Respir Dis
, vol.143
, pp. 1121-1129
-
-
Pugin, J.1
Auckenthaler, R.2
Mili, N.3
Janssens, J.P.4
Lew, P.D.5
Suter, P.M.6
-
18
-
-
42549162568
-
-
Clarithromycin for intravenous injection: clinical expert report [data on file]. Abbott Park, IL: Abbott Laboratories, 1998.
-
Clarithromycin for intravenous injection: clinical expert report [data on file]. Abbott Park, IL: Abbott Laboratories, 1998.
-
-
-
-
19
-
-
19944429484
-
Ventilator associated pneumonia: Comparison between quantitative and qualitative cultures of tracheal aspirates
-
Camargo LFA, De Marco FV, Barbas CSV, et al. Ventilator associated pneumonia: comparison between quantitative and qualitative cultures of tracheal aspirates. Crit Care 2004; 8:R422-30.
-
(2004)
Crit Care
, vol.8
-
-
Camargo, L.F.A.1
De Marco, F.V.2
Barbas, C.S.V.3
-
21
-
-
33644909052
-
Evaluation of an intervention designed to decrease the role of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use
-
Madars-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the role of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006; 27:155-69.
-
(2006)
Infect Control Hosp Epidemiol
, vol.27
, pp. 155-169
-
-
Madars-Kelly, K.J.1
Remington, R.E.2
Lewis, P.G.3
Stevens, D.L.4
-
22
-
-
30344451643
-
Epidemiology and outcomes of health-care-associated pneumonia: Results froma large US database of culture-positive pneumonia
-
Kollef MH, Shorr A, Tabak YP, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results froma large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
-
(2005)
Chest
, vol.128
, pp. 3854-3862
-
-
Kollef, M.H.1
Shorr, A.2
Tabak, Y.P.3
Liu, L.Z.4
Johannes, R.S.5
-
24
-
-
27744470133
-
Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria
-
Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 2005; 31:1488-94.
-
(2005)
Intensive Care Med
, vol.31
, pp. 1488-1494
-
-
Giantsou, E.1
Liratzopoulos, N.2
Efraimidou, E.3
-
25
-
-
0346993417
-
Incidence, etiology, and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation
-
Rello J, Lorente C, Diaz E, et al. Incidence, etiology, and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation. Chest 2003; 124:2239-43.
-
(2003)
Chest
, vol.124
, pp. 2239-2243
-
-
Rello, J.1
Lorente, C.2
Diaz, E.3
-
26
-
-
13244291394
-
Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
-
Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55:10-21.
-
(2005)
J Antimicrob Chemother
, vol.55
, pp. 10-21
-
-
Amsden, G.W.1
-
27
-
-
0141816759
-
Azithromycin: In patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial
-
Saiman L, Marshall BC, Mayer-Hamblett, et al. Azithromycin: in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749-56.
-
(2003)
JAMA
, vol.290
, pp. 1749-1756
-
-
Saiman, L.1
Marshall, B.C.2
Hamblett, M.3
-
28
-
-
0037190575
-
Long term azithromycin in children with cystic fibrosis: A randomized, placebo-controlled crossover trial
-
Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002; 360:978-84.
-
(2002)
Lancet
, vol.360
, pp. 978-984
-
-
Equi, A.1
Balfour-Lynn, I.M.2
Bush, A.3
Rosenthal, M.4
-
30
-
-
4544277113
-
Regulatory effects of macrolides on bacterial virulence: Potential role as quorum sensing inhibitors
-
Takeda K, Standiford TJ, Pechère JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum sensing inhibitors. Curr Pharm Des 2004; 10:3055-65.
-
(2004)
Curr Pharm Des
, vol.10
, pp. 3055-3065
-
-
Takeda, K.1
Standiford, T.J.2
Pechère, J.C.3
Yamaguchi, K.4
-
31
-
-
33846245519
-
Clarithromycin in the treatment of RSV bronchiolitis: A double-blind, randomised, placebo-controlled trial
-
Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2007; 29:91-7.
-
(2007)
Eur Respir J
, vol.29
, pp. 91-97
-
-
Tahan, F.1
Ozcan, A.2
Koc, N.3
|